We read with great interest and appreciated the letter by Ronner and colleagues1 appearing in a recent issue of Blood Advances. Although these authors give recognition to our efforts to address a highly debated issue that could have implications in management of patients with polycythemia vera (PV), they also raise some important criticisms on the…
Key PointsVen can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML.Ven plus 7+3 chemotherap
In recent years, several novel CD3×CD20 bispecific immunotherapies have received accelerated approval for the treatment of follicular lymphoma and diffuse
Key PointsVen can be safely used in combination with 7+3 chemotherapy for remission induction in patients with newly diagnosed AML.Ven plus 7+3 chemotherap
In this issue of Blood Advances, Gauthier et al1 report on a phase 1 clinical trial conducted at Fred Hutchinson Cancer Research Center which tested…
In this issue of Blood Advances, Nieves et al1 present findings from SACRED (Stroke Avoidance for Children in República Dominicana; ClinicalTrials.gov iden
Key Points. Based on duration and timing of thrombocytopenia, we introduce T-ICAHT as a novel grading that expands on the existing N-ICAHT system.Severe (G
